Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How is it possible that, with the patents and intellectual property they possess, the company is worth .0004 right now? Even with the pending but not approved R/S the market is saying the company is worth 125K? If true, what have they been doing all these years? What about Baylor, etc? It makes no sense. Ugly.
Thanks Fort Uitous. I believe we have a right to the minutes to shareholder meetings as well. I'm not sure how to go about that since they don't even answer an email.
cc:
Thank you for your work over the years and our present IP portfolio.
Just a reminder to all shareholders and as reaffirmed by a recent Delaware Supreme Court ruling, all Delaware Corporations have a duty by law to provide financial statements to a shareholder upon enquiry. Delaware Corporations are not entitled to enforce an NDA.
Regulation FD does not apply to Delaware Corporations when they de-register from the SEC.
https://courts.delaware.gov/Opinions/Download.aspx?id=337340
I agree with these sentiments, and suggest that the remaining shareholders create a private online chat room for those who wish to explore our options.
We were asked by MYMX management months ago not to take any legal action, as they were focused on selling the company. However, that clearly was not full disclosure…they were also planning this option. If what they are doing is illegal, we have every right to respond.
What this company and management is doing is criminal. They don't have to delist from the OTC but they're choosing to do so. They have until the end of December to get the share price over .01 and are choosing not to wait. All they had to do was a 2 to 1 reverse stock split to meet the requirement. They're doing a 2,000 to 1 reverse stock split. The price of .0023 per share they talked about in the filing was for any leftover shares you held under 2,000. They weren't giving partial shares. There were over 600 shareholders just this summer. According to their last filing they will now be under 300. How is that possible. Were there 300 shareholders with less than 2,000 shares? Something doesn't seem right. Somehow being under 300 it allows the company to terminate the registration of its common stock and suspend its reporting obligations. That's why they're doing a 2,000 to 1 split. It must be their magic number. The management has kept us in the dark for the last 3 years but at least we've had the filings to gain some info. Now we'll be totally in the dark. How many times has the management responded to any of your emails. I know I've emailed them multiple times and not once have they responded.
The fact that the company is choosing to be delisted during a period of time in which they have announce the sale of the company should be terms for a shareholder lawsuit on its own. I believe this is what the insiders wanted. If they orchestrated the price to fall to get the number of shareholders down below 300 that's criminal. If they can do that to the smaller shareholder, what confidence do you have they will treat the rest of us fairly when they sell the company. After going private they'll probably structure some deal to benefit the insiders only.
It doesn't matter if we think their patents are worth something and the company will sell eventually. I believe a shareholder lawsuit should be looked into. before it's too late. Like it's been said, after they go private how will any of the shareholders be able to communicate.
Thanks very much for the support, Phosphene. I know that you are well versed in this, and wish you the best in negotiating the difficult decisions currently on the table. Longtime holders will lose a major portion of our investment in the short term, and if we continue to support MYMX it will be with significantly less access to company information in the future.
I did and still do believe that the patents held and the research MYMX engages in remain invaluable to the biotech field. My inclination is to remain a shareholder. But as the company goes private we have no voice - how will we glean information about their work? We don’t know where their new office is, will have no access to regularly scheduled filings, and decisions
affecting investor shares will be solely determined by insiders.
Would there be ways to share information among ourselves going forward? If MYMX is subsequently sold, would we be compensated equitably?
Am reading the new MYMX filings now - thanks, AhsokaXC - and would like to hear others’ thoughts on this development. The timing of this, on the cusp of Dr. Ruprecht’s report on the NIH HIV research project, seems perhaps relevant.
Hope life's good Castaways!
Heartbreaking for a longtime believer and remaining common holder like myself.
I haven't seen the Schedule 13E-3 and Schedule 14C either.
Ulrich Burkhard has done this "going private" rodeo move on another company some years back.
The company resurfaced after a couple years of darkness and investors recouped some of their money back after some venture capital groups acquired it.
"Going private" protects the identity of MYMX's shot callers as bankruptcy would expose them.
It also keeps Mr. Kempers presentable at Biopole.
Enjoy your weekend and keep your head up.
You can find it here. The filing has a share price too. https://www.sec.gov/edgar/browse/?CIK=0000927761
Thank you for these very important updates,Templar. I went to the SEC website yesterday, but find no new filings for MYMX. They no longer trade on the U.S. stock market, and we do not know their new address. They have not yet communicated directly with shareholders, and I am not sure when they plan to do so.
This is obviously not the news we hoped for. The reverse split acknowledges management’s responsibility to shareholders. We are still waiting the results of important research that they are involved in. Since they are going private, we need to know what our shares are worth…I assume that information will be in the next filings.
Do we as shareholders have a plan moving forward amid these major changes?
I would suggest all shareholders read the entire filing.
New 8k filing is out. It says it got a notice from the OTC about being delisted after falling under .01 for 30 days. I questioned the .001 in their previous filing. It didn't seem right, and it wasn't. They're also doing a reverse stock split of 2,000 to 1. It says it's a "going private" transaction. Here's part of the filing.
The transaction is a “going private” transaction under Section 13(e) of the Exchange Act and the Company will file a Schedule 13E-3 with the SEC that
contains additional information about the transaction, which stockholders are urged to read carefully and in its entirety. Pursuant to rules adopted by the
SEC under the Exchange Act, a Schedule 14C information statement relating to the matters described above will be filed with the SEC and sent or provided
to the stockholders of the Company. The Schedule 13E-3 and Schedule 14C will be available at www.sec.gov
I know they were giving her more time to finish after everyone else’s research was cut off. So hopefully it’s a positive result, and not just a published paper.
I thought Dr. Ruprecht's NIH work would've been completed by now.
Hope Mr. Kempers will share some good news in the November 10-Q.
"The happiness of your life depends upon the quality of your thoughts." - Marcus Aurelius
Does anyone know when Ruth’s work is supposed to be finished?
WHO recommends another malaria vaccine. Developed by Oxford University.
Mymetics cooperated with Oxford University in regard of a malaria vaccine.
Sureley another department. ;-(
(German text)
https://www.tagesschau.de/wissen/gesundheit/who-malaria-impfstoff-kinder-100.html
Hello Extrinsic55.
I always used their $82 million Astellas deal as a gauge.
That's coming up on a decade and things change but it was a benchmark.
Since then they've "worked" with Sanofi, eTheRNA, IO Biotech, etc. and a cast of others that followers have never heard the results from their efforts.
The patent with Catalent from MACAVIVA is solid but sits dormant.
Stallergenes approved the Anergis work but still chose to go with alum.
Asthma reduction is a big claim to be made public. No interest from big pharma?
Dr. Peter Hotez had a televised platform and captive audience for two years and never mentioned his MYMX work once.
PCI Biotech?
Were they actually even "working" with these companies?
Audited on taxes and got dropped by BDO. Mom and Pop accounting firm in Spokane, WA took over.
Longtime counsel Ernie Stern jumped ship.
The company that has them up "for sale" doesn't even list them on their web page.
Dr. Thomas Staehelin's run off to the wild, wild west (Serbia).
Mr. Kempers is at the pawn shop with office furniture.
Nobody has this bad of luck.
Stock Holders of Record: Anyone agree with this interpretation
Insider Holder Name Report
Date Time Shares Owned
Directly
Indirectly Total
Shares Owned Filing
Round Enterprises Ltd. 10% Owner 2015-09-04 07:12:30 141,006,552 Form 3
LUEBKE ERNST Chief Financial Officer 2007-06-22 11:05:38 10,079,418 Form 4
KEMPERS Ronald Hugo Gerard President and CEO and CFO 2023-01-31 15:08:47 17,000,000 Form 4
Staehelin Thomas Director 2010-12-20 15:59:38 0 12,812,907 12,812,907 Form 3
KHD HUMBOLDT WEDAG INTERNATIONAL LTD. 10% Owner 2006-01-17 13:50:49 1,705,250
6,715,790 8,421,040 Form 4
ROCHET CHRISTIAN Director 2009-07-28 11:44:33 5,459,862 Form 4
Stegmann Antonius Johannes CSO 2014-01-29 15:31:55 4,150,000 Form 3
Martin Jacques Francois CEO 2010-12-02 12:29:24 1,930,307 2,080,307 Form 4
Stern Ernest M Director 2008-06-23 17:30:08 1,500,000 Form 4
Fleury Sylvain CSO 2014-03-19 21:41:09 1,150,000 Form 4
Ruegg Marcel B. Director 2023-01-31 15:08:52
PCI Biotech, preclinical research collaborator, performs write down of share capital.
September 1, 2023.
https://finance.yahoo.com/news/pci-biotech-write-down-share-090400583.html
https://www.accesswire.com/viewarticle.aspx?id=713978
New address of shared office space has yet to be updated on Mymetics or Biopole website.
+41 216534535
"Net cash provided in investing activities was €92 during the six-months ended June 30, 2023, due to sales of office equipment in Leiden, and €2 used during the same period in 2022, related to new IT equipment in Epalinges." - August 10-Q
Good job on selling used office equipment in Leiden.
Why was new IT equipment in Epalinges needed if all you do is submit three 10-Q's and an annual report?
How about an update on the ongoing final studies of HIV vaccine candidate?
Is Uncle Ulrich relocating back to South America after maximizing shareholder value for common holders?
https://www.marcuardfamilyoffice.com/news/25-years-of-marcuard-family-office/
And where is MFO heading in the next five years?
I’ll leave that question to the younger partners!
In order for insiders to be selling now there would have to be a filing, especially with the company up for sale. They own more than 50% of the outstanding shares so you wouldn't be able to buy enough for a takeover. They wouldn't let that happen. The las two springs the stock has made a pop. If they didn't announce a bid process in February, you probably could have gotten 6-8 cents this spring sometime even without them putting out PR's. Two and a half years ago it was trading at a price 100 times more than it is now. Now that's creating shareholder value.
If anything, I think Kempers friends and family are probably buying shares now. As siar said Kempers did buy more shares before they put the company up for sale. In one of the recent filings, he said they were in discussion with an international biotech company. That was worded differently than before.
The question is if they make a deal will the shareholders outside the inner circle benefit. I'm not sure how they could structure a deal without including us. My patience is running thin with management. Maybe we should take control of the situation. Give them an option of letting us know what's really going, sell the company by a certain date or we start a shareholder lawsuit and tie them up in court for years. They have more to lose than we do. Just a thought.
"90mill debt wouldn't or couldn't that be written off in some way."
It could, of course. But as long as the company has assets, these debt holders have priority.
And (I think all) of that debt is convertible. They will try to get back as much as possible. Shareholders will get the - possibly non-existent - rest.
"It's evident that its unlikely that it will ever be paid."
Is it? I don't think so. And it seems certain to me, that Mr. Kempers thinks he can get much more than 100 million for the company. Remember, he recently did put his money in the company. If he thinks that debt will never be payable, he would have destroyed his money.
Never.
I am sure he has at least one seriously interested company, but that company or companies are not willing to pay enough. Who could resent them trying to make a bargain. The problem seems to me, that there are no competing interested parties and therefore are not going to outbid each other.
Thanks that certainly makes things much clearer. 90mill debt wouldn't or couldn't that be written off in some way. It's evident that its unlikely that it will ever be paid.
Most of the shares are not in public float, probably not all shareholders would sell at that price, and one would buy a company with, what, 90 million debt that could be converted into shares.
But you can send a buyout offer to Mr. Kempers. I am wondering if he would reply.
In my opinion he is trying to win a huge gamble. If we would and could fall to less than 0.0005 I would buy a few million shares as a lotto ticket.
Technically wouldn't you only have to get controlling interest 51% or higher to have control and access to all assets and company control. Change company direction.
At current level 303M shares price 454K
Help Here. 303M shares outstanding. Purchase all for .002 per share that's $ 606,000.00 Isn't that kind of a steal! Anyone know what the cost to buy a company to have complete control of an OTC traded company is? I'm researching it now but I remember its been some years when I wanted my company to go public. I thought it was around 200k to buy and get a clear company to start out with. For 600k could one have rights to the patents and tradeable company? Any Thoughts
According to insider peek there are no insider shareholders, I hope i am wrong
Trying to Calculate Large Volume of Shares. Insider selling??. Market Makers getting preferential buying at low prices to facilitate a push higher??. or is this just stick a fork in it its over. SAGA continues. Just like reality TV. Just need more feedback to keep it interesting. A few hints or somethings from MYMX would always be fun..
And it continues today... April was bad but the volume in that span was comparatively low - less than 3 million shares over two days. Even with the 300% drop it was kind of hard to stick a fork in it at that time. Now it's just hard to believe that with all they claim to have in tech and patents that the stock traded down to triple zeros. What have they been doing all these years?
I didn't have high hopes after April but I thought there would at least be an offer close to the average of the insiders. The recent action seems to indicate that the market expects the insiders to feather their nest and zero out everyone else. Maybe the company is sitting on some positive info but the market action isn't confirming that,
Good luck to all
Moving Help Needed : August 31st. 9:00AM
Excellent opportunity for Biopole Startup's to get hands on experience of reducing burn rate.
Volunteers requested with a strong back and positive attitude.
Call +41 216534535 if you can assist.
Location:
Biopole
Lysine Building
Route de la Corniche 4
1066 Epalinges
"the office lease agreement for Epalinges has been terminated as of August 31, 2023, and the Company is leasing a shared office space on a three month’s lease basis." - August 2023. 10-Q.
Delisting at under .001. But we’ve also been under .01 for a long time too. Who knows what’s going on or what will happen.
Based on the Latest Trading Looks Like .0001 is coming. The Boat is sinking. I think someone stated if it hits .0001 automatic delisting. Is that what I remember. Do I have that right. Found It from Templar I believe " In addition, the Company has been informed that in the event that the Company’s closing bid price falls below $0.001 at any time for five consecutive "
In the last 2 days I believe someone or group has acquired approx 5 million shares @ an average price of .002. Now this is just speculation. I think IMHO that this market drop was intentional. In the next 5 to 10 days will watch and see how many more shares are traded and the action. So many times I have seen a stock drop just like this only to be catapulted forward to new heights. To much silence from Kemper and kronies makes me think that something is on the table. Maybe its just hopefull thinking that Kemper is a good person looking out for himself and his shareholders but I here to wait and see. Next week should be interesting either way..
If were admitting selling. I sold off some shares to start the selling yesterday. Bought back the shares at a lower price. I'm going to be here till the end
4 million shares purchased below.0022 approx yesterday. Lets see if those shares are sold or held for higher stock price. In other words the market makers. I still think we get news shortly. Hopefully its good news..
What other company puts itself up for sale and loses 95% of its value. This company should have gone private years ago. They've had total disregard for shareholders outside the inner circle. They stopped putting out PR's a few years ago. The only way we get any info is through quarterly reports. 6 months after they put the company up for sale, they claw back a patent and then say it will take several months to do so. That was for a partial payment on 6 million owed so how much could that be worth? If that holds up any sale of this company that's horrible planning. Kempers should not be getting a paycheck now. They said they don't care if the stock gets delisted. Maybe it doesn't matter to them, but it makes a big difference to those outside the company holding the shares. Some brokers won't allow you to trade the stock once it gets delisted. It will just sit there in your account until they either make a sale or you take a tax loss. I don't blame anyone for selling. I'm choosing to hold at this point. The only good thing in the last 2 filings were they're taking the effort to claw back the patent and Round and Eardley are still loaning the company money. Unfortunately, this company has lost shareholder trust. I'm pissed off at management. How can you not be. At this point they could pull something dirty and screw long term shareholders. Don't know. They know darn well what's going on and refuse to let us in on it. It's unfortunate because some long-term shareholders are selling at a loss now. Six months ago, Kempers said a lawsuit would slow down the process of selling the company. They need to get their arse in gear or that may not be avoidable.
Nobody with any experience in the market would be mad at YOU. The demise of MYMX is not your fault.
Maybe Kempers and his cronies are planning to take this thing private and completely screw over retail investors. I certainly feel like they screwed me over but that's the game we're playing -- we have to make guesses and gamble and sit in the shadows and hope to find money that falls out of the pockets of the insiders who know what's going on.
I gambled and lost here. Oh well. Best of luck to all who ride it out.
Thanks SP. It’s bonkers they can’t give us more information we know they have.
I think that was a real selloff today.
I took my loss in April and it hurt. see post 27397
I wonder if it will be possible to follow where the patent ends up.
I want u all to know it was me selling today. I am agitated by a couple of things. I didn't want to sell. I still don't. I still carry a good amount of shares. This isn't my intention to make you all mad. I think Mr Kempers has been less than forthright. I apologize to all of you but once I saw the ask at .086 I was irritated. I am done selling at the moment but I'm hoping that the powers that b give us some sort of update other than these stupid q's....they owe all of us some sort of explanation. Most of all Phosphene...You my friend will always be someone I admire. I am irritated in general with the whole market. Love you all and wish us nothing but great things in our lives. I'll keep pushing even though the stack is stacked against us.
Here is a thought. It's officially over.
I hope you are correct or else I have a lot of tax write offs for losses lol
Here is a thought. 6.5 million shares intentionally sold to market makers so when news does come out on a sale the market makers are making money to push the stock high and higher. I am going to go with that and see how the next 20 days roll out. I would think that if something is going to happen its going to happen soon. The market makers are going to want to capitalize on the large volume of trade today. Looking for another drop tomorrow to .001 then push possible Monday or Tuesday. I have seen it before push it low then Boom.. Good Luck to the ones who held me included..
Is leadership trying to intentionally take this company private?
They don't want bankruptcy because it would expose and identify the names on the insider trust.
Dr. Thomas Staehelin could write a check and make it all go away.
Long time holder.
My faith is being challenged today.
I'm not selling at these levels.
Hope tomorrow is a better day for all.
What a performance, Mr. Kempers. Will the loyal investors loose everything?
Another -0.0004 and MYMX will prbably be delisted.
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27659
|
Created
|
09/25/02
|
Type
|
Free
|
Moderators |
http://www.mymetics.com/
COMPANY OVERVIEW
https://www.mymetics.com/files/8116/2081/0445/May21-Mymetics_Overview.pdf
Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands.
Focused on developing next generation preventative vaccines for infectious diseases.
Mymetics core technology and expertise are in the use of virosomes,
lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.
Objective: "Build small / medium size innovative R&D virosome vaccine company with strong
partnerships, Phase II – III clinical vaccine pipeline and have optionality for M&A or sale."
Current Share Structure:
Outstanding Shares: 303.7 million (as of 01/18/2019 unchanged since 2014)
Floating Shares: 79.8 million* (a/o 01/18/19)
(https://www.otcmarkets.com/stock/MYMX/profile)
Rationale and Impact of MACIVIVA
With few exceptions, commercialized vaccines are generally delivered by injection through the intramuscular or subcutaneous route.
Vaccines contain immunogens classically found within a large variety of biological compounds such as peptides, proteins, glycoproteins and sometimes carbohydrates and lipids.
These immunogens may trigger the immune system for producing antibodies and/or cytotoxic T cells for preventing the pathogen transmission or blocking and/or slowing down the disease progression.
However, these vaccines generally exist as liquid formulation that are inherently prone to physical and/or chemical modifications. The cold chain storage is still fundamental for preserving the
bioactivity of most liquid and freeze-dried vaccines. For reconstituted freeze dried vaccines, they harbor important instability and must be used within hours and kept refrigerated. Vaccine degradation generally takes place
during shipment and/or storage of liquid or lyophilized products, which may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection.
There is growing evidence that solid dosage formats (e.g. powder form) for vaccines may offer several advantages over the liquid formulations, such as the prevention of molecular motion and shear-induced degradation,
and slowing down modifications and degradation reactions involving water and oxygen radicals, resulting in improved stability, enhanced shelf-life of vaccines and greatly simplified logistics.
MYMETICS BV
Expertise: R&D on virosome formulations
Project responsability: Investigating and compiling the results about the physical and biochemical properties of the virosome-based vaccines obtained by spray-drying and lyophilization.
MYMETICS SA
Expertise : Non-GMP and GMP virosome production, clinical development
Project responsability: Excipient selection for liquid virosomes, supervising the non-GMP and GMP manufacturing of the liquid virosomes and development of analytical methods.
UPPERTON LIMITED
Expertise: Non-GMP and GMP Spray drying
Project responsability: Identification of excipients and experimental conditions suitable for virosome spray drying, production of non-GMP and GMP powder forms for nasal and oral delivery.
CATALENT U.K. SWINDON ZYDIS LIMITED
Expertise: Zydis technology for fast-dissolving tablet, world leader in drug formulation and distribution
Project responsability: Identification of excipients and experimental conditions suitable for virosome lyophylization, according to the Zydis technology, non-GMP and GMP tablets for sublingual delivery.
CHIMERA BIOTEC GMBH
Expertise: Ultra sensitive immunoassays development and bioanalysis based on Imperacer® (Immuno-PCR) technology.
Project responsability: Immunogenicity study in animals with spray-dried and lyophilized virosomes. Imperacer® immunoassay development and evaluation of the vaccine-induced antibody response.
BACHEM AG
Expertise: R&D, non-GMP and GMP manufacturing of API, world supplier
Project responsability: Process Development and manufacture of peptide P1, GMP-grade, including development and validation of analytical methods.
Vaccines are poorly accessible in developing countries
Vaccines require cold-chain storage and are often delivered by injection, which is undesirable, less safe and more expensive to administer.
Developing thermostable solid form vaccines through non-invasive routes may represent a long-term global solution to the vaccination challenge (Amorij, 2008).
Virosomes are an efficient vaccine delivery system
Virosomes are spherical, unilamellar lipid-based carriers, intercalated with functional glycoproteins to reflect the natural virus, however the lack of viral RNA means there is no risk of infection
(Figure 1). Virosomes can be tagged with different antigens and adjuvants, meaning they can be tailored to target different viruses, and offer increased immunogenicity over inactivated viruses.
Currently, virosomal influenza vaccines are only available in liquid form (Amorij, 2008).
Spray drying can produce dry powders for a range of dosage forms, including inhaled or nasal drug delivery.
A dry powder is formed when a liquid feed solution or suspension is atomised using a spray nozzle, and rapidly dried using hot air. However, while the drying process is gentle due to evaporative cooling,
there is still the potential to stress and inactivate vaccine components. It has been found that subunit and live-attenuated vaccines (and other delicate molecules such as proteins)
can be protected during processing b by incorporating them in an amorphous sugar matrix, which also offers longer term stability during storage (Kanojia, 2016).
A method has been developed to produce a powder form of virosome based influenza vaccine using spray-drying.
Formulations have been optimised for oral and nasal delivery.
Virosomal technology is approved by the FDA for use in humans, and has a high safety profile
Virosomes are biodegradable, biocompatible, and non-toxic12
No disease-transmission risk
No autoimmunogenity or anaphylaxis10
Broadly applicable with almost all important drugs (anticancer drugs, proteins, peptides, nucleic acids, antibiotics, fungicides)
Enables drug delivery into the cytoplasm of target cell
Promotes fusion activity in the endolysosomal pathway
Protects drugs against degradation
Intellectual Property
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |